Multiomic identified biomarkers and progression-free survival in patients with WM receiving ibrutinib. Kaplan-Meier curves for PFS and risk tables for (A) GPR18, (B) WNK2, (C) CHST15, (D) PRDM15, (E) GPER1, (F) DUSP22, and (G) KIF21A. Tables show progression for high and low expressors of each candidate. Risk tables show progression data for each group.